Jun 2026 (Q2 FY26) — Aug 12, 2026
Kura Oncology Q2 FY26 — KOMZIFTI Achieves Market Leadership in New Patient Starts
Read the full callKura Oncology (KURA) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Kura Oncology earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 20.9 | +36.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -349.8 | +125.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -68.3 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$9.36 +3.08% · +$0.28
Performance −4.9% 1Y
1Y: $9.84 on 17 Oct 2025 → $9.36. High $13.59 (25 Aug 2026), low $7.4 (5 Feb 2026).
- Previous close
- $9.08
- 52-week range
- $7.4 – $13.59
- One year
- −6.31%
Overview
- Symbol
- KURA
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Kura Oncology earnings calls (KURA)
Financials
What the filings say
Net profit, year on year: −3% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | — | — | 14 | 15 | 21 | 17 | 18 | 21 |
| Expenses | — | — | 79 | 88 | — | — | 97 | 94 |
| Operating profit | -60 | -22 | -65 | -73 | -80 | -86 | -79 | -73 |
| Operating margin | — | — | −458.6% | −475.3% | −385.5% | −497.6% | −431.5% | −349.8% |
| Other income | 5 | 5 | 7 | 7 | 6 | 5 | 5 | 5 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -54 | -17 | -57 | -66 | -74 | -81 | -73 | -68 |
| Tax rate | — | — | −0.4% | — | — | −0.1% | −0.0% | −0.0% |
| Net profit | -54 | -19 | -57 | -66 | -74 | -81 | -73 | -68 |
| EPS ($ per share) | -0.63 | — | -0.66 | -0.75 | -0.85 | — | -0.83 | -0.77 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -150 | -213 | -303 | -433 | -569 | -721 | -895 | -1,174 |
| Total liabilities | 21 | 23 | 36 | 27 | 36 | 52 | 347 | 564 |
| Fixed assets | — | 0 | 2 | 3 | 3 | 2 | 2 | 8 |
| Total assets | 182 | 242 | 647 | 534 | 456 | 449 | 760 | 738 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -49 | -55 | -70 | -105 | -110 | -125 | 134 | -64 |
| Cash from investing | -79 | -46 | -100 | -127 | 33 | 16 | -102 | -13 |
| Cash from financing | 133 | 111 | 469 | -3 | 39 | 95 | 154 | 2 |
| Net cash flow | 5 | 10 | 300 | -235 | -39 | -14 | 187 | -75 |
| Capital expenditure | — | — | -2 | -1 | -1 | -0 | -0 | -7 |
| Free cash flow | — | — | -72 | -106 | -111 | -125 | 134 | -71 |
Insider filings
58 filings between Nov 13, 2025 and Sep 29, 2026.
Open market
decisions to buy or sellPurchases
$2.35M
2 purchases by 1 insider
Sales
$3.84M
40 sales by 7 insiders
30% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 11
- Award — granted as compensation
- 5
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| WILSON TROY EDWARD | $2.35M | — | Aug 24, 2026 |
| Leoni Mollie | — | $1.52M | Sep 29, 2026 |
| Bair Teresa Brophy | — | $700.7K | Sep 28, 2026 |
| Powl Brian T. | — | $663.4K | Sep 29, 2026 |
| Burrows Francis | — | $467.5K | Sep 24, 2026 |
| FORD KATHLEEN | — | $224.9K | Sep 29, 2026 |
| DOYLE THOMAS JAMES | — | $159.5K | Sep 28, 2026 |
| Hasnain Faheem | — | $109.8K | Dec 9, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 29, 2026 | FORD KATHLEEN Chief Operating Officer | Sale 10b5-1 plan | 3,668 | $39.4K |
| Sep 29, 2026 | Powl Brian T. Chief Commercial Officer | Sale | 15,430 | $165.9K |
| Sep 29, 2026 | Leoni Mollie Chief Medical Officer | Sale | 28,802 | $309.6K |
| Sep 28, 2026 | Powl Brian T. Chief Commercial Officer | Sale | 8,000 | $84.5K |
| Sep 28, 2026 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | 4,607 | $48.4K |
| Sep 28, 2026 | Leoni Mollie Chief Medical Officer | Sale | 12,448 | $130.7K |
| Sep 28, 2026 | FORD KATHLEEN Chief Operating Officer | Sale 10b5-1 plan | 6,906 | $72.5K |
| Sep 28, 2026 | Bair Teresa Brophy Chief Legal Officer | Sale 10b5-1 plan | 8,442 | $88.6K |
| Sep 28, 2026 | Powl Brian T. Chief Commercial Officer | Sale | 9,020 | $94.7K |
| Sep 24, 2026 | Burrows Francis Chief Scientific Officer | Option exercise | 30,000 | $184.5K |
| Sep 24, 2026 | Burrows Francis Chief Scientific Officer | Sale | 20,726 | $224.5K |
| Aug 24, 2026 | WILSON TROY EDWARD President and CEO | Purchase | 100,000 | $1.24M |
| Aug 21, 2026 | Powl Brian T. Chief Commercial Officer | Sale 10b5-1 plan | 4,345 | $51.7K |
| Aug 19, 2026 | Bair Teresa Brophy Chief Legal Officer | Sale 10b5-1 plan | 31,487 | $397.7K |
| Aug 17, 2026 | WILSON TROY EDWARD President and CEO | Purchase | 100,000 | $1.11M |
| Jun 18, 2026 | Leoni Mollie Chief Medical Officer | Sale 10b5-1 plan | 84,929 | $834.3K |
| May 21, 2026 | Powl Brian T. Chief Commercial Officer | Sale 10b5-1 plan | 10,000 | $110.0K |
| May 19, 2026 | Powl Brian T. Chief Commercial Officer | Sale 10b5-1 plan | 339 | $3.1K |
| May 19, 2026 | FORD KATHLEEN Chief Operating Officer | Sale 10b5-1 plan | 2,257 | $20.5K |
| May 18, 2026 | Bair Teresa Brophy Chief Legal Officer | Sale 10b5-1 plan | 2,256 | $21.2K |
| Mar 23, 2026 | WILSON TROY EDWARD President and CEO | Option exercise | 6,103 | $37.5K |
| Mar 18, 2026 | Malley Thomas Director | Option exercise | 10,000 | $31.2K |
| Jan 27, 2026 | Leoni Mollie Chief Medical Officer | Sale | 951 | $8.0K |
| Jan 27, 2026 | Leoni Mollie Chief Medical Officer | Sale | 1,341 | $11.3K |
| Jan 27, 2026 | Powl Brian T. Chief Commercial Officer | Sale | 4,842 | $41.0K |
| Jan 27, 2026 | Powl Brian T. Chief Commercial Officer | Sale | 1,572 | $13.3K |
| Jan 27, 2026 | Burrows Francis Chief Scientific Officer | Sale | 1,311 | $11.1K |
| Jan 27, 2026 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | 881 | $7.5K |
| Jan 27, 2026 | Leoni Mollie Chief Medical Officer | Sale | 3,655 | $30.9K |
| Jan 27, 2026 | Leoni Mollie Chief Medical Officer | Sale | 2,233 | $18.9K |
| Jan 27, 2026 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | 2,226 | $18.8K |
| Jan 27, 2026 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | 695 | $5.9K |
| Jan 27, 2026 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | 1,114 | $9.4K |
| Jan 27, 2026 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | 2,226 | $18.8K |
| Jan 27, 2026 | Bair Teresa Brophy Chief Legal Officer | Sale | 4,777 | $40.4K |
| Jan 27, 2026 | Bair Teresa Brophy Chief Legal Officer | Sale | 2,335 | $19.8K |
| Jan 27, 2026 | Bair Teresa Brophy Chief Legal Officer | Sale | 4,096 | $34.7K |
| Jan 27, 2026 | FORD KATHLEEN Chief Operating Officer | Sale | 1,813 | $15.3K |
| Jan 2, 2026 | Powl Brian T. Chief Commercial Officer | Award | 50,000 | $0 |
| Jan 2, 2026 | Bair Teresa Brophy Chief Legal Officer | Award | 50,000 | $0 |
| Jan 2, 2026 | FORD KATHLEEN Chief Operating Officer | Award | 50,000 | $0 |
| Jan 2, 2026 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Award | 21,250 | $0 |
| Jan 2, 2026 | Leoni Mollie Chief Medical Officer | Award | 50,000 | $0 |
| Dec 18, 2025 | Burrows Francis Chief Scientific Officer | Sale | 23,726 | $231.9K |
| Dec 18, 2025 | Burrows Francis Chief Scientific Officer | Option exercise | 35,000 | $168.0K |
| Dec 9, 2025 | Hasnain Faheem Director | Sale | 10,000 | $109.8K |
| Dec 9, 2025 | Hasnain Faheem Director | Option exercise | 10,000 | $31.2K |
| Nov 14, 2025 | FORD KATHLEEN Chief Operating Officer | Sale 10b5-1 plan | 6,902 | $77.1K |
| Nov 14, 2025 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | 4,539 | $50.7K |
| Nov 14, 2025 | Leoni Mollie Chief Medical Officer | Sale | 15,485 | $173.1K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Kura Oncology, Inc.
Free account. Everything above stays public.
Write why you follow Kura Oncology, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading